Apogee Therapeutics Surges to Record $133 on $10.9 Billion AbbVie Acquisition on Monday

According to AbbVie's announcement, Apogee Therapeutics (APGE) stock hit a record high of $133 on Monday (June 23) after the pharmaceutical giant agreed to acquire the biotechnology company for $135.11 per share in an all-cash deal valued at approximately $10.9 billion. The acquisition targets Apogee's antibody-based treatment pipeline for inflammatory diseases. On the same trading day, Intel (INTC) reached an all-time high of $141.45, and Keel Infrastructure (KEEL) climbed to a four-year high of $7.37.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments